Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients

21. März 2014 aktualisiert von: Giovanni Taveggia

Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic

The investigators evaluated the effectiveness of the application of analysing treadmill, muscle strengthening and balance training compared to a control intervention in patients with diabetic neuropathy.

Studienübersicht

Detaillierte Beschreibung

Recent studies witnessed how physical exercise may interrupt the devastating decrease of muscle performance in DSP and further experiments are underway to find more exercises for the recovery of motor function impairment. In fact the rehabilitation treatment, that aims at reducing motor disability, preserving gait functions and preventing falling risks, is an interesting therapeutic approach. Literature recommends balance re-training exercises, muscle strengthening, selective stretching and retraining of motor activity.

New technologies produced in the recent decades different devices used in strengthening exercises (electromechanical dynamometers), balance recovery (balance platforms) and gait (analyzing treadmills) have visual feedbacks through which the patients may independently monitor accuracy and intensity of their exercises, being therefore strongly motivated and resulting in a high training intensity. These technologies are often used in rehabilitation of different patients, but are rarely employed for DSP.

The purpose of this case control study was to examine the effectiveness of the application of analysing treadmill, muscle strengthening and balance training compared to a control intervention in patients with diabetic neuropathy.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

36

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Bergamo
      • Sarnico, Bergamo, Italien, 24067
        • Habilita, Ospedale di Sarnico

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • The participants need to have a history of diabetes mellitus type 2, >3 years, (i.e., time from the diagnosis or the beginning of first related signs or symptoms),
  • A diagnosis of Distal Sensorimotor Polyneuropathy associated,
  • Able to walk autonomously, eventually with a aid.

Exclusion Criteria:

  • Scoring less than 5 points on the Functional Independence Measure (FIM) (7) locomotion scale,
  • Presenting articular ankyloses, contractures, spasms with important locomotion effects,
  • Presenting bony instability affecting lower limb functionality (unconsolidated fractures, vertebral instability, severe osteoporosis),
  • In presence of attendant clinicopathological conditions contraindicating the rehabilitation treatment (respiratory insufficiency, cardiac/circulatory failure, osteomyelitis, phlebitis and different other conditions),
  • In presence of cutaneous lesions at lower limbs,
  • Scoring less than 22 points on the Mini Mental State Examination (MMSE),
  • Exhibit important behavioural diseases involving aggressivity or psychotic disorders.
  • Had received prior interventions for Distal Sensorimotor Polyneuropathy.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Technological Rehabilitation
Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).

The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.

Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.

The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions.

Andere Namen:
  • Dynamometric isokinetic device: Biodex System 4,
  • Balance device: Biodex Balance System SD,
  • Analyzing treadmill: Biodex Gait Trainer 3.
Aktiver Komparator: Control Rehabilitation
Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
When needed, more than on e therapist are employed in the intervention for safety reasons.
Andere Namen:
  • Manuelle Rehabilitation mit dem Therapeuten.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline of 6-minute walk test
Zeitfenster: 1 day after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 6-minute walk test (6MWT) is used to assess endurance.

The 6MWT quantifies functional mobility based on the distance in meters traveled in six minutes. This outcome is a measure of endurance and is particularly significant to evaluate the possibility to perform continuative tasks, that are particularly important for the rehabilitation of diabetic patients and are relevant for an autonomous life. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

1 day after the treatment
Change from Baseline of 10-metres walk test
Zeitfenster: 1 day after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 10-metres walking test is used to assess gait speed.

The speed is quantified with the 10-metres walk test (TWT) over the ground. The gait speed measurement is performed over the middle 6 meters of the TWT and patients are asked to walk at their comfortable speed. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

1 day after the treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Followup change from Baseline of 6-minute walk test
Zeitfenster: 30 days after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 6-minute walk test (6MWT) is used to assess endurance.

The 6MWT quantifies functional mobility based on the distance in meters traveled in six minutes. This outcome is a measure of endurance and is particularly significant to evaluate the possibility to perform continuative tasks, that are particularly important for the rehabilitation of diabetic patients and are relevant for an autonomous life. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

30 days after the treatment
Followup change from Baseline of 10-metres walk test
Zeitfenster: 30 days after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 10-metres walking test is used to assess gait speed.

The speed is quantified with the 10-metres walk test (TWT) over the ground. The gait speed measurement is performed over the middle 6 meters of the TWT and patients are asked to walk at their comfortable speed. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

30 days after the treatment
Change from Baseline of the Functional Independence Measure (FIM)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Tinetti scale
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Resting Energy Expenditure (REE)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Respiratory Rate (RR)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Heart Rate (HR)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the oxygen saturation (SpO2)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the maximal oxygen consumption (VO2 max)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the expired minute volume (Ve)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the fraction of expired air that is oxygen (FeO2)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Systolic Blood Pressure (SBP)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Diastolic Blood Pressure (DBP)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Glycated Hemoglobin (HbA1c)
Zeitfenster: 1 day after the treatment
1 day after the treatment
Followup change from Baseline of the Functional Independence Measure (FIM)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Tinetti scale
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Resting Energy Expenditure (REE)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Respiratory Rate (RR)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Heart Rate (HR)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the oxygen saturation (SpO2)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the maximal oxygen consumption (VO2 max)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the expired minute volume (Ve)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the fraction of expired air that is oxygen (FeO2)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Systolic Blood Pressure (SBP)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Diastolic Blood Pressure (DBP)
Zeitfenster: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Glycated Hemoglobin (HbA1c)
Zeitfenster: 30 days after the treatment
30 days after the treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Giovanni Taveggia, MD, Habilita, Ospedale di Sarnico

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. September 2013

Primärer Abschluss (Tatsächlich)

1. November 2013

Studienabschluss (Tatsächlich)

1. November 2013

Studienanmeldedaten

Zuerst eingereicht

14. August 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. August 2013

Zuerst gepostet (Schätzen)

21. August 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

24. März 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. März 2014

Zuletzt verifiziert

1. März 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • Habilita-RAR-02
  • 201206180007491711110 (Andere Kennung: Bioethic board)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Diabetische Neuropathien

Klinische Studien zur Technological Rehabilitation

Abonnieren